Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Rick Winningham will engage in a Fireside Chat on September 9, 2025, at 1:30 PM EDT.
The company will offer in-person meeting opportunities for interested investors through H.C. Wainwright representatives. A live webcast will be available online, with a replay accessible on Theravance's website for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) ha annunciato la propria partecipazione al 27° Annual Global Investment Conference di H.C. Wainwright a New York. L’amministratore delegato Rick Winningham parteciperà a un Fireside Chat il 9 settembre 2025 alle 13:30 EDT.
La società offrirà incontri di persona per gli investitori interessati tramite i rappresentanti di H.C. Wainwright. Sarà disponibile una diretta webcast e la registrazione resterà accessibile sul sito di Theravance per 30 giorni dopo l’evento.
Theravance Biopharma (NASDAQ: TBPH) anunció su participación en la 27.ª Conferencia Anual Global de Inversión de H.C. Wainwright en Nueva York. El director ejecutivo Rick Winningham participará en un Fireside Chat el 9 de septiembre de 2025 a la 1:30 PM EDT.
La compañía ofrecerá citas presenciales para los inversores interesados a través de los representantes de H.C. Wainwright. Habrá una retransmisión en directo por internet y la grabación estará disponible en la web de Theravance durante 30 días tras el evento.
Theravance Biopharma (NASDAQ: TBPH)가 뉴욕에서 열리는 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. CEO 릭 위닝햄(Rick Winningham)이 2025년 9월 9일 동부시간 오후 1시 30분에 파이어사이드 채팅에 참여합니다.
회사는 H.C. Wainwright의 담당자를 통해 관심 있는 투자자들에게 대면 미팅 기회를 제공할 예정입니다. 온라인 생중계가 제공되며, 행사 후 30일 동안 Theravance 웹사이트에서 다시보기로 시청할 수 있습니다.
Theravance Biopharma (NASDAQ: TBPH) a annoncé sa participation à la 27e conférence annuelle mondiale d'investissement H.C. Wainwright à New York. Le PDG Rick Winningham participera à une Fireside Chat le 9 septembre 2025 à 13h30 EDT.
La société proposera des rencontres en personne pour les investisseurs intéressés via les représentants de H.C. Wainwright. Un webdiffusion en direct sera disponible en ligne et la rediffusion sera accessible sur le site de Theravance pendant 30 jours après l'événement.
Theravance Biopharma (NASDAQ: TBPH) hat seine Teilnahme an der 27. jährlichen Global Investment Conference von H.C. Wainwright in New York angekündigt. CEO Rick Winningham wird an einem Fireside Chat am 9. September 2025 um 13:30 Uhr EDT teilnehmen.
Das Unternehmen bietet interessierten Investoren über die Vertreter von H.C. Wainwright persönliche Treffen an. Eine Live-Webcast-Übertragung wird online verfügbar sein, und eine Aufzeichnung steht auf der Theravance-Website für 30 Tage nach der Veranstaltung zum Abruf bereit.
- None.
- None.
Rick Winningham, CEO, will participate in a Fireside Chat on Tuesday, September 9 at 1:30 PM EDT (10:30 AM PDT / 6:30 PM IST).
Management will be hosting in-person meetings during the event. Interested investors should contact their H.C. Wainwright representative to request a meeting.
A live webcast of the event may be accessed here or on the "Events and Presentation" page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543498.html
SOURCE Theravance Biopharma, Inc.
FAQ
When is Theravance Biopharma (TBPH) presenting at the H.C. Wainwright Conference?
How can investors access Theravance Biopharma's H.C. Wainwright Conference presentation?
How can investors schedule meetings with Theravance Biopharma management at the H.C. Wainwright Conference?
Who will represent Theravance Biopharma at the H.C. Wainwright Conference?
